The gut microbiome and the pathogenesis of trans-arterial chemoembolization-associated liver injury

References

[1] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma J Hepatol 2025 82 315 74

[2] Jaber F,Cholankeril G,El-Serag HB. Contemporary epidemiology of hepatocellular carcinoma: understanding risk factors and surveillance strategies J Can Assoc Gastroenterol 2024 7 331 45 PMC11477987

[3] Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind J-FH. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data Hepatology 2016 64 106 16

[4] Li J,Liu Y,Zheng R,Qu C,Li J. Molecular mechanisms of TACE refractoriness: directions for improvement of the TACE procedure Life Sci 2024 342 122540

[5] Lapidot Y,Amir A,Nosenko R.et al. Alterations in the gut microbiome in the progression of cirrhosis to hepatocellular carcinoma mSystems 2020 5 e00153 20 PMC7300357

[6] Zhang N,Gou Y,Liang S.et al. Dysbiosis of gut microbiota promotes hepatocellular carcinoma progression by regulating the immune response J Immunol Res 2021 2021 4973589 PMC8551979

[7] Schneider KM,Mohs A,Gui W.et al. Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment Nat Commun 2022 13 3964 PMC9270328

[8] Huang M,Ji Q,Huang H,Wang X,Wang L. Gut microbiota in hepatocellular carcinoma immunotherapy: immune microenvironment remodeling and gut microbiota modification Gut Microbes 2025 17 2486519 PMC11970798

[9] Liu Q,Duan ZP,Ha DK,Bengmark S,Kurtovic J,Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis Hepatology 2004 39 1441 9

[10] Wang X,Zhang B,Jiang R. Microbiome interplays in the gut-liver axis: implications for liver cancer pathogenesis and therapeutic insights Front Cell Infect Microbiol 2025 15 1467197 PMC11810975

[11] Li R,Liu J,Ye F.et al. Microbial metabolism dysfunction induced by transarterial chemoembolization aggravates postprocedural liver injury in HCC J Hepatol 2026 84 808 22

[12] Bian CF,Wang Y,Yu A.et al. Gut microbiota changes and biological mechanism in hepatocellular carcinoma after transarterial chemoembolization treatment Front Oncol 2022 12 1002589 PMC9577458

[13] Trebicka J,Macnaughtan J,Schnabl B,Shawcross DL,Bajaj JS. The microbiota in cirrhosis and its role in hepatic decompensation J Hepatol 2021 75 S67 81 PMC8973011

[14] Wang J,He XD,Zhang YC. Antibiotic prophylaxis in transarterial therapy of hepatocellular carcinoma: a meta-analysis Can J Gastroenterol 2012 26 85 91 PMC3275410

[15] Nishida AH,Ochman H. Rates of gut microbiome divergence in mammals Mol Ecol 2018 27 1884 97 PMC5935551

[16] Scepanovic P,Hodel F,Mondot S.et al. Milieu Intérieur Consortium A comprehensive assessment of demographic, environmental, and host genetic associations with gut microbiome diversity in healthy individuals Microbiome 2019 7 130 PMC6744716